Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis.
Gottlieb AB, Miller B, Lowe N, Shapiro W, Hudson C, Bright R, Ling M, Magee A, McCall CO, Rist T, Dummer W, Walicke P, Bauer RJ, White M, Garovoy M.
Gottlieb AB, et al.
J Cutan Med Surg. 2003 May-Jun;7(3):198-207. doi: 10.1007/s10227-002-0118-1.
J Cutan Med Surg. 2003.
PMID: 12717587
Clinical Trial.